中国药物警戒 ›› 2025, Vol. 22 ›› Issue (4): 472-474.
DOI: 10.19803/j.1672-8629.20240510

• 安全与合理用药 • 上一篇    下一篇

阿帕他胺片联合醋酸戈舍瑞林缓释植入剂致皮疹1例分析

曾吉1, 张进科2, 王莉2, 陈俊3, 孟旭东4, 宁婧5, 黄成6   

  1. 1安徽中医药大学附属马鞍山市中医院药剂科,安徽 马鞍山 243000;
    2安徽中医药大学附属马鞍山市中医院肿瘤科,安徽 马鞍山 243000;
    3马鞍山市人民医院急诊科,安徽 马鞍山 243000;
    4马鞍山市人民医院普外科,安徽 马鞍山 243000;
    5苏州大学附属第三医院皮肤科,江苏 常州 213000;
    6安徽医科大学药学院安徽省创新药物研究所安徽省炎症与免疫介导性疾病实验室,安徽 合肥 230032
  • 收稿日期:2024-07-26 发布日期:2025-04-17
  • 作者简介:曾吉,女,硕士,主管药师,临床药学、炎症与免疫药理学。
  • 基金资助:
    安徽省转化医学研究院科研基金项目（2021zhyx-B06）

One Case of Rash Caused by Apalutamide Combined with Goserelin

ZENG Ji1, ZHANG Jinke2, WANG Li2, CHEN Jun3, MENG Xudong4, NING Jing5, HUANG Cheng6   

  1. 1Department of Pharmacy, Ma’anshan Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Traditional Chinese Medicine, Ma’anshan Anhui 243000, China;
    2Department of Oncology, Ma’anshan Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Traditional Chinese Medicine, Ma’anshan Anhui 243000, China;
    3Department of Emergency, Ma’anshan People’s Hospital, Ma’anshan Anhui 243000, China;
    4Department of General Surgery, Ma’anshan People’s Hospital, Ma’anshan Anhui 243000, China;
    5Department of Dermatology, the Third Affiliated Hospital of Soochow University, Changzhou Jiangsu 213000, China;
    6Laboratory of Inflammation and Immune-Mediated Diseases, Anhui Provincial Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei Anhui 230032, China
  • Received:2024-07-26 Published:2025-04-17

PDF (PC)

61

摘要： 目的 分析1例阿帕他胺片联合醋酸戈舍瑞林缓释植入剂治疗过程中出现药物性皮疹的病例,为临床安全合理用药提供参考。方法 基于1例阿帕他胺片联合醋酸戈舍瑞林缓释植入剂导致皮疹的病例分析,结合国内外相关文献及经验,为该患者制定个性化药学监护方案并提出用药调整建议。结果 结合患者用药史、药品说明书及相关文献分析,阿帕他胺片和醋酸戈舍瑞林缓释植入剂为皮疹不良反应可疑药物,立即停用阿帕他胺片,给予抗过敏等对症治疗,同时调整可能与之存在相互作用的他汀类药物并密切监测其血脂水平,约3周左右全身皮疹和瘙痒好转。结论 临床使用阿帕他胺片联合醋酸戈舍瑞林缓释植入剂时,应密切关注可能发生的皮疹不良反应,及时调整药物治疗方案,提升用药依从性。

关键词: 阿帕他胺, 戈舍瑞林, 皮疹, 瘙痒, 药品不良反应

Abstract: Objective To investigate a case of drug-induced rash during treatment with apalutamide tablets combined with goserelin acetate sustained-release implant in order to provide data for safe and rational medications. Methods After analysis of one case of rash caused by the combined use of apalutamide tablets and goserelin acetate sustained-release implant, an individualized plan for pharmacotherapeutic monitoring was developed based on related literature and clinical experience. Additionally, recommendations for new medications were provided. Results In-depth analysis of the patient’s medication history, prescriptions and relevant literature identified apalutamide tablets and goserelin acetate sustained-release implant as the suspected cause of the adverse reaction. Apalutamide was promptly discontinued, and antihistamine therapy was initiated. Concurrently, the statin regimen was adjusted to mitigate potential drug interactions, with close monitoring of lipid profiles. The patient’s systemic rash and pruritus showed marked improvement within about three weeks. Conclusion Potential rash-related adverse reactions may occur when apalutamide is administered in combination with goserelin acetate sustained-release implants. Quick regimen adjustments and proactive monitoring are critical to medication compliance and patient safety.

Key words: Apalutamide, Goserelin, Rash, Itching, Adverse Drug Reaction

中图分类号: